| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveal Neoplasms | 22 | 2024 | 194 | 6.670 |
Why?
|
| Retinal Neoplasms | 20 | 2023 | 137 | 4.510 |
Why?
|
| Retinoblastoma | 19 | 2023 | 189 | 4.120 |
Why?
|
| Melanoma | 23 | 2024 | 5598 | 2.460 |
Why?
|
| Biopsy, Fine-Needle | 11 | 2020 | 699 | 1.890 |
Why?
|
| Macular Edema | 5 | 2024 | 90 | 1.860 |
Why?
|
| Brachytherapy | 11 | 2024 | 1005 | 1.640 |
Why?
|
| Intravitreal Injections | 7 | 2024 | 140 | 1.400 |
Why?
|
| Gene Expression Profiling | 10 | 2024 | 5183 | 1.370 |
Why?
|
| Ranibizumab | 4 | 2024 | 71 | 1.300 |
Why?
|
| Retinal Diseases | 4 | 2024 | 189 | 1.290 |
Why?
|
| Iodine Radioisotopes | 5 | 2024 | 387 | 1.290 |
Why?
|
| Vitrectomy | 5 | 2024 | 109 | 1.280 |
Why?
|
| Endophthalmitis | 3 | 2021 | 82 | 1.260 |
Why?
|
| Retinal Perforations | 3 | 2024 | 27 | 1.220 |
Why?
|
| Antigens, Neoplasm | 4 | 2024 | 1591 | 1.170 |
Why?
|
| Sclera | 2 | 2018 | 62 | 1.150 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2024 | 1266 | 1.110 |
Why?
|
| Retina | 4 | 2024 | 543 | 1.020 |
Why?
|
| Visual Acuity | 10 | 2024 | 861 | 0.940 |
Why?
|
| Glaucoma, Neovascular | 1 | 2023 | 2 | 0.930 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2024 | 41 | 0.900 |
Why?
|
| Eye Injuries | 1 | 2023 | 51 | 0.880 |
Why?
|
| Vitreous Body | 6 | 2023 | 115 | 0.880 |
Why?
|
| Optic Nerve Diseases | 1 | 2023 | 111 | 0.810 |
Why?
|
| Masks | 1 | 2021 | 56 | 0.770 |
Why?
|
| Tomography, Optical Coherence | 7 | 2024 | 544 | 0.760 |
Why?
|
| Neoplasm Seeding | 2 | 2017 | 67 | 0.690 |
Why?
|
| Choroid Neoplasms | 3 | 2018 | 45 | 0.690 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2024 | 1586 | 0.680 |
Why?
|
| Neutropenia | 1 | 2023 | 1001 | 0.660 |
Why?
|
| Ultrasonography | 9 | 2019 | 1941 | 0.660 |
Why?
|
| Infusions, Intra-Arterial | 4 | 2023 | 176 | 0.620 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2018 | 58 | 0.600 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 14003 | 0.590 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 10756 | 0.560 |
Why?
|
| RNA, Neoplasm | 1 | 2019 | 810 | 0.540 |
Why?
|
| Radiation Injuries | 2 | 2024 | 1472 | 0.540 |
Why?
|
| Catheterization, Peripheral | 1 | 2018 | 160 | 0.540 |
Why?
|
| Eye Enucleation | 7 | 2019 | 87 | 0.530 |
Why?
|
| Retrospective Studies | 31 | 2024 | 39817 | 0.510 |
Why?
|
| Neoplasms, Vascular Tissue | 2 | 2012 | 11 | 0.510 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 2358 | 0.500 |
Why?
|
| Melphalan | 4 | 2023 | 875 | 0.470 |
Why?
|
| Laser Therapy | 4 | 2008 | 465 | 0.470 |
Why?
|
| Topotecan | 3 | 2023 | 248 | 0.460 |
Why?
|
| Epiretinal Membrane | 3 | 2024 | 15 | 0.450 |
Why?
|
| Radiotherapy | 3 | 2020 | 1862 | 0.440 |
Why?
|
| Body Weight | 1 | 2018 | 1336 | 0.440 |
Why?
|
| Eye Neoplasms | 3 | 2023 | 257 | 0.440 |
Why?
|
| Fluorescein Angiography | 5 | 2023 | 148 | 0.420 |
Why?
|
| Male | 42 | 2024 | 129048 | 0.420 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2024 | 224 | 0.410 |
Why?
|
| Iris Diseases | 1 | 2011 | 17 | 0.400 |
Why?
|
| Conjunctival Neoplasms | 1 | 2013 | 125 | 0.390 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 31062 | 0.390 |
Why?
|
| Humans | 65 | 2024 | 271967 | 0.390 |
Why?
|
| Laser Coagulation | 5 | 2021 | 141 | 0.390 |
Why?
|
| Eyelid Neoplasms | 1 | 2013 | 197 | 0.390 |
Why?
|
| Neurofibromatosis 2 | 2 | 2010 | 33 | 0.390 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 237 | 0.380 |
Why?
|
| Melanosis | 2 | 2021 | 16 | 0.360 |
Why?
|
| Infant | 16 | 2023 | 13995 | 0.360 |
Why?
|
| Aged | 23 | 2024 | 73494 | 0.360 |
Why?
|
| Middle Aged | 25 | 2024 | 90447 | 0.360 |
Why?
|
| Female | 40 | 2024 | 149251 | 0.350 |
Why?
|
| Abscess | 1 | 2011 | 192 | 0.350 |
Why?
|
| Ophthalmic Artery | 3 | 2023 | 31 | 0.340 |
Why?
|
| Eye Evisceration | 1 | 2009 | 6 | 0.330 |
Why?
|
| Candidiasis | 1 | 2011 | 280 | 0.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2024 | 9097 | 0.320 |
Why?
|
| Carboplatin | 4 | 2023 | 880 | 0.320 |
Why?
|
| Blindness | 1 | 2009 | 80 | 0.310 |
Why?
|
| Eye Infections, Bacterial | 2 | 2021 | 96 | 0.310 |
Why?
|
| Follow-Up Studies | 10 | 2024 | 15264 | 0.310 |
Why?
|
| Retinal Vessels | 1 | 2008 | 83 | 0.290 |
Why?
|
| Retinal Detachment | 1 | 2008 | 86 | 0.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5570 | 0.280 |
Why?
|
| Adult | 19 | 2024 | 81964 | 0.270 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2024 | 1904 | 0.260 |
Why?
|
| Treatment Outcome | 11 | 2024 | 33911 | 0.250 |
Why?
|
| Basement Membrane | 2 | 2024 | 145 | 0.250 |
Why?
|
| Paraneoplastic Syndromes, Ocular | 1 | 2024 | 2 | 0.250 |
Why?
|
| Eukaryotic Initiation Factor-1 | 1 | 2024 | 15 | 0.240 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2024 | 66 | 0.240 |
Why?
|
| Prostaglandins, Synthetic | 1 | 2024 | 3 | 0.230 |
Why?
|
| Vitreous Hemorrhage | 1 | 2023 | 10 | 0.230 |
Why?
|
| Prostaglandins | 1 | 2024 | 84 | 0.230 |
Why?
|
| RNA Splicing Factors | 1 | 2024 | 153 | 0.220 |
Why?
|
| Retinitis | 1 | 2023 | 19 | 0.220 |
Why?
|
| Eye Infections, Viral | 1 | 2023 | 29 | 0.220 |
Why?
|
| Melanocytes | 1 | 2024 | 241 | 0.220 |
Why?
|
| Hydroxychloroquine | 1 | 2023 | 31 | 0.220 |
Why?
|
| Genes, Neoplasm | 2 | 2017 | 317 | 0.220 |
Why?
|
| Hyperthermia, Induced | 2 | 2004 | 511 | 0.210 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 14647 | 0.210 |
Why?
|
| Ophthalmology | 2 | 2020 | 203 | 0.210 |
Why?
|
| Retinitis Pigmentosa | 1 | 2023 | 85 | 0.200 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2019 | 141 | 0.200 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2003 | 146 | 0.200 |
Why?
|
| Choroid Diseases | 1 | 2021 | 23 | 0.200 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 9052 | 0.200 |
Why?
|
| Ciliary Body | 2 | 2011 | 34 | 0.190 |
Why?
|
| Lacrimal Apparatus | 1 | 2023 | 186 | 0.190 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 12035 | 0.190 |
Why?
|
| Young Adult | 9 | 2024 | 22167 | 0.190 |
Why?
|
| Pain | 1 | 2009 | 1698 | 0.180 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2003 | 331 | 0.180 |
Why?
|
| Uvea | 1 | 2019 | 4 | 0.180 |
Why?
|
| Dry Eye Syndromes | 1 | 2023 | 257 | 0.170 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 3362 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2019 | 51 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2019 | 41 | 0.170 |
Why?
|
| Prospective Studies | 5 | 2024 | 13398 | 0.170 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 882 | 0.160 |
Why?
|
| Phosphoproteins | 1 | 2024 | 1229 | 0.160 |
Why?
|
| Child, Preschool | 13 | 2020 | 17070 | 0.160 |
Why?
|
| Incidence | 3 | 2023 | 5858 | 0.160 |
Why?
|
| Fundus Oculi | 1 | 2018 | 66 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 550 | 0.150 |
Why?
|
| Surgical Flaps | 1 | 2024 | 882 | 0.150 |
Why?
|
| Choroid | 1 | 2017 | 43 | 0.150 |
Why?
|
| Child | 9 | 2023 | 30576 | 0.150 |
Why?
|
| Femoral Artery | 1 | 2018 | 204 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 2 | 2019 | 1387 | 0.130 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 685 | 0.130 |
Why?
|
| DNA, Neoplasm | 2 | 2020 | 1972 | 0.130 |
Why?
|
| Iatrogenic Disease | 1 | 2016 | 197 | 0.130 |
Why?
|
| ROC Curve | 1 | 2018 | 1247 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 214 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1103 | 0.120 |
Why?
|
| Triamcinolone Acetonide | 2 | 2016 | 39 | 0.110 |
Why?
|
| Transcriptome | 2 | 2024 | 1953 | 0.110 |
Why?
|
| Lasers, Semiconductor | 2 | 2010 | 11 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2020 | 1346 | 0.110 |
Why?
|
| Biomarkers | 2 | 2024 | 5098 | 0.110 |
Why?
|
| Vincristine | 3 | 2010 | 1584 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 10369 | 0.100 |
Why?
|
| Carcinoma | 1 | 2023 | 2624 | 0.100 |
Why?
|
| Iris Neoplasms | 1 | 2011 | 3 | 0.100 |
Why?
|
| Risk Factors | 4 | 2023 | 18028 | 0.100 |
Why?
|
| Cryotherapy | 2 | 2017 | 67 | 0.100 |
Why?
|
| Monitoring, Intraoperative | 2 | 2010 | 265 | 0.090 |
Why?
|
| Retinal Artery | 1 | 2010 | 17 | 0.090 |
Why?
|
| Candida albicans | 1 | 2011 | 187 | 0.090 |
Why?
|
| Retinoblastoma Protein | 2 | 2010 | 342 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2010 | 16630 | 0.090 |
Why?
|
| Mutation | 4 | 2024 | 15952 | 0.090 |
Why?
|
| United States | 3 | 2021 | 16018 | 0.090 |
Why?
|
| Tuberculosis, Ocular | 1 | 2009 | 4 | 0.090 |
Why?
|
| Retinal Vasculitis | 1 | 2009 | 9 | 0.080 |
Why?
|
| Macula Lutea | 1 | 2010 | 46 | 0.080 |
Why?
|
| Time Factors | 3 | 2024 | 13129 | 0.080 |
Why?
|
| Retinal Horizontal Cells | 1 | 2008 | 15 | 0.080 |
Why?
|
| Biopsy | 2 | 2013 | 3543 | 0.080 |
Why?
|
| Etoposide | 2 | 2010 | 905 | 0.080 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 1401 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 7474 | 0.080 |
Why?
|
| Postoperative Complications | 3 | 2016 | 5695 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 3 | 2011 | 1596 | 0.080 |
Why?
|
| Appointments and Schedules | 1 | 2008 | 97 | 0.080 |
Why?
|
| Pseudophakia | 1 | 2008 | 72 | 0.080 |
Why?
|
| Nevus, Pigmented | 1 | 2008 | 116 | 0.070 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 92 | 0.070 |
Why?
|
| Salvage Therapy | 2 | 2008 | 2123 | 0.070 |
Why?
|
| Molecular Biology | 1 | 2008 | 181 | 0.070 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2008 | 97 | 0.070 |
Why?
|
| Podophyllotoxin | 1 | 2007 | 65 | 0.070 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2007 | 55 | 0.070 |
Why?
|
| Operating Rooms | 1 | 2008 | 128 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2010 | 609 | 0.070 |
Why?
|
| Eye Diseases | 1 | 2008 | 127 | 0.070 |
Why?
|
| Infant, Newborn | 5 | 2010 | 8631 | 0.070 |
Why?
|
| Prognosis | 3 | 2024 | 22542 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2013 | 7925 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2008 | 335 | 0.070 |
Why?
|
| Biometry | 1 | 2008 | 249 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2011 | 1553 | 0.070 |
Why?
|
| Refraction, Ocular | 1 | 2008 | 299 | 0.070 |
Why?
|
| Cataract Extraction | 1 | 2008 | 212 | 0.060 |
Why?
|
| Phacoemulsification | 1 | 2008 | 234 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2008 | 623 | 0.060 |
Why?
|
| Endotamponade | 1 | 2024 | 9 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 288 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 534 | 0.060 |
Why?
|
| Pupil | 1 | 2004 | 64 | 0.060 |
Why?
|
| Lenses, Intraocular | 1 | 2008 | 393 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 3177 | 0.060 |
Why?
|
| Macrophages | 1 | 2010 | 1377 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 4897 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 895 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2003 | 140 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2008 | 2035 | 0.050 |
Why?
|
| Genetic Counseling | 1 | 2004 | 417 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2008 | 1068 | 0.050 |
Why?
|
| Diseases in Twins | 1 | 2002 | 109 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 3512 | 0.050 |
Why?
|
| Optic Nerve | 1 | 2003 | 140 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2023 | 363 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2023 | 457 | 0.050 |
Why?
|
| Prednisone | 1 | 2003 | 1036 | 0.040 |
Why?
|
| Fibrosarcoma | 1 | 2000 | 142 | 0.040 |
Why?
|
| Methotrexate | 2 | 2017 | 1033 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 1966 | 0.040 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2000 | 159 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2010 | 187 | 0.040 |
Why?
|
| Brain Neoplasms | 2 | 2010 | 4992 | 0.040 |
Why?
|
| Injections | 2 | 2010 | 287 | 0.040 |
Why?
|
| Adolescent | 4 | 2010 | 32743 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 2269 | 0.040 |
Why?
|
| Microscopy, Acoustic | 1 | 2017 | 26 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2011 | 4362 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2023 | 1668 | 0.040 |
Why?
|
| Sclerosis | 2 | 2010 | 84 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2003 | 3147 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2016 | 258 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2003 | 3243 | 0.030 |
Why?
|
| Macular Degeneration | 1 | 2016 | 123 | 0.030 |
Why?
|
| Diabetic Retinopathy | 1 | 2016 | 153 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2024 | 10260 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2011 | 2288 | 0.030 |
Why?
|
| Eye Color | 1 | 2011 | 8 | 0.020 |
Why?
|
| Bacteria | 1 | 2016 | 652 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2011 | 186 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2010 | 55 | 0.020 |
Why?
|
| Polyethylene | 1 | 2010 | 22 | 0.020 |
Why?
|
| Orbital Implants | 1 | 2010 | 29 | 0.020 |
Why?
|
| Internationality | 1 | 2011 | 206 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2017 | 9476 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2003 | 7794 | 0.020 |
Why?
|
| Pyrazinamide | 1 | 2009 | 15 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4503 | 0.020 |
Why?
|
| Retinal Neovascularization | 1 | 2009 | 19 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2010 | 296 | 0.020 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2010 | 182 | 0.020 |
Why?
|
| Isoniazid | 1 | 2009 | 72 | 0.020 |
Why?
|
| Endoglin | 1 | 2008 | 41 | 0.020 |
Why?
|
| Ophthalmoscopes | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 524 | 0.020 |
Why?
|
| Interferometry | 1 | 2008 | 26 | 0.020 |
Why?
|
| Tuberculin Test | 1 | 2009 | 136 | 0.020 |
Why?
|
| Telecommunications | 1 | 2008 | 27 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 351 | 0.020 |
Why?
|
| Hypoxia | 1 | 2011 | 476 | 0.020 |
Why?
|
| Microglia | 1 | 2010 | 176 | 0.020 |
Why?
|
| Prosthesis Implantation | 1 | 2010 | 242 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2008 | 107 | 0.020 |
Why?
|
| Rifampin | 1 | 2009 | 220 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2008 | 169 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2008 | 235 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2008 | 242 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2007 | 7259 | 0.020 |
Why?
|
| Light | 1 | 2008 | 281 | 0.020 |
Why?
|
| Oxygen | 1 | 2011 | 795 | 0.020 |
Why?
|
| Antitubercular Agents | 1 | 2009 | 349 | 0.020 |
Why?
|
| Anesthesiology | 1 | 2008 | 146 | 0.020 |
Why?
|
| Cataract | 1 | 2008 | 231 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 782 | 0.020 |
Why?
|
| Actins | 1 | 2008 | 615 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 982 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 2495 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2010 | 646 | 0.020 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2008 | 339 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2008 | 910 | 0.020 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2009 | 486 | 0.010 |
Why?
|
| Mice | 3 | 2011 | 36023 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 1772 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 2363 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2008 | 1435 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 1177 | 0.010 |
Why?
|
| Tissue Embedding | 1 | 2003 | 29 | 0.010 |
Why?
|
| Ruthenium Radioisotopes | 1 | 2002 | 8 | 0.010 |
Why?
|
| Twins, Dizygotic | 1 | 2002 | 48 | 0.010 |
Why?
|
| Animals | 3 | 2011 | 62782 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 7300 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 6515 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 6904 | 0.010 |
Why?
|
| Survival Rate | 1 | 2011 | 12545 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 6203 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2002 | 830 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 4819 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2000 | 4067 | 0.010 |
Why?
|